Eversept Partners, LP Clovis Oncology, Inc. Transaction History

Eversept Partners, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.63 - $2.96 $18,900 - $88,800	-30,000 Closed	0 $0
Q1 2022 Nov 08, 2023	BUY	$1.43 - $3.14 $42,900 - $94,200	30,000 New	30,000 $60,000
Q1 2022 May 16, 2022	BUY	$1.43 - $3.14 $42,900 - $94,200	30,000 New	30,000 $61,000
Q1 2018 May 14, 2018	SELL	$50.12 - $67.72 $821,817 - $1.11 Million	-16,397 Closed	0 $0
Q4 2017 Nov 08, 2023	BUY	$57.69 - $84.58 $945,942 - $1.39 Million	16,397 New	16,397 $1.11 Billion
Q4 2017 Feb 12, 2018	BUY	$57.69 - $84.58 $945,942 - $1.39 Million	16,397	16,397 $1.12 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.